Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revolution Picks Up Remains Of EQRx In All-Stock Deal

Deal Aimed At Beefing Up Balance Sheet

Executive Summary

Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.

You may also be interested in...



Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.

BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials

BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.

Chinese PD-1s Eye US Approvals Despite Lack Of Action Dates

Although Novartis/BeiGene’s tislelizumab and Coherus /Junshi’s toripalimab have not received a new Prescription Drug User Fee Act (PDUFA) decision date for their biologics license applications in the US, the companies remain hopeful that potential approvals will be granted in the third quarter at the earliest.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel